Joohi Jimenez-Shahed, M.D.

Transcription

1 (Page 1 of 7) Joohi Jimenez-Shahed, M.D. Associate Professor of Neurology Baylor College of Medicine Associate Director, Neurology Residency Program Baylor College of Medicine Director, Deep Brain Stimulation Program Baylor College of Medicine CONTACT INFORMATION Joohi Jimenez-Shahed, M.D. Baylor Neurology Baylor College of Medicine Medical Center, McNair Campus 7200 Cambridge St., 9th Floor, MS: BCM609 Houston, Texas Tel: Fax: jshahed@bcm.edu SPECIALITY Parkinson's Disease Tremors Movement Disorders CERTIFICATION American Board of Psychiatry and Neurology, Neurology EDUCATION M.D., Baylor College of Medicine, Houston, Texas Internship,, Baylor College of Medicine, Houston, Texas Residency, Neurology, Duke University Medical Center, Durham, N.C. Fellowship, Parkinson's Disease and Movement Disorders, Baylor College of Medicine, Houston, Texas PROFESSIONAL INTERESTS Parkinson's Disease Essential and Other Tremors Movement Disorders Deep Brain Stimulation Huntington's Disease Tourette Syndrome Spasticity Botulinum Toxin Injections CLINIC APPOINTMENTS CONSULT

2 (Page 2 of 7) CLINIC LOCATION Baylor Neurology Baylor College of Medicine Medical Center, McNair Campus 7200 Cambridge St., 9th Floor, MS: BCM609 Houston, Texas BCM HONORS Rising Star Clinician Award, Baylor College of Medicine, GRANTS (NIH FUNDING) Jimenez-Shahed J (Principal Investigator). Clinical Center for the Study of Neuroprotection From PD. National Institute of Neurological Disorders and Stroke U10 grant (RFA-NS ); $116,596 awarded in direct costs, Sept. 30, 2002 Feb. 14, CURRENT COMMITTEE MEMBERSHIPS Baylor College of Medicine (BCM) Department representative, Faculty Senate, present JOURNAL PUBLICATIONS Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng FG, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. JAMA Neurol. 2018;:. PMID: Patel N, Combs H, York M, Phan C, Jimenez-Shahed J. Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. J Neuropsychiatry Clin Neurosci. 2018;:appineuropsych PMID: Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8): PMID: Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89(11): PMID: Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21): PMID: Ramirez-Zamora A, Giordano JJ, Gunduz A, Brown P, Sanchez JC, Foote KD, et al. Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think Tank. Front Neurosci. 2017;11:734. PMID: Ramirez-Zamora A, Giordano JJ, Gunduz A, Brown P, Sanchez JC, Foote KD, et al. Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think Tank. Front Neurosci. 2017;11:734. PMID: Deeb W, Giordano JJ, Rossi PJ, Mogilner AY, Gunduz A, Judy JW, et al. Proceedings of the fourth annual deep brain stimulation think tank: A review of emerging issues and technologies. Front Integr Neurosci. 2016;10:38. PMID: Deeb W, Rossi PJ, Porta M, Visser-Vandewalle V, Servello D, Silburn P, et al. The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work? Front Neurosci. 2016;10:170. PMID: Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, et al. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016;22(7): PMID: Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. Jama. 2016;316(1): PMID: Jimenez-Shahed J, Telkes I, Viswanathan A, Ince NF. GPi Oscillatory Activity Differentiates Tics from the Resting State, Voluntary Movements, and the Unmedicated Parkinsonian State. Front Neurosci. 2016;10:436. PMID: Jimenez-Shahed J. A review of current and novel levodopa formulations for the treatment of Parkinson's disease. Ther Deliv. 2016;7(3): PMID:

3 (Page 3 of 7) Kious BM, Jimenez-Shahed J, Shprecher DR. Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70: PMID: Mehanna R, Jimenez-Shahed J, Itin I. Three cases of levodopa-resistant parkinsonism after radiation therapy. Am J Case Rep. 2016;17: PMID: Telkes I, Jimenez-Shahed J, Viswanathan A, Abosch A, Ince NF. Prediction of STN-DBS Electrode Implantation Track in Parkinson's Disease by Using Local Field Potentials. Front Neurosci. 2016;10:198. PMID: Jimenez-Shahed J. Design challenges for stimulation trials of Tourette's syndrome. Lancet Neurol. 2015;14(6): PMID: Baizabal-Carvallo JF, Kagnoff MN, Jimenez-Shahed J, Fekete R, Jankovic J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014;85(5): PMID: Parkinson Study Group QE Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5): PMID: Patel N, Jimenez-Shahed J. Simultaneous improvement of tics and parkinsonism after pallidal DBS. Parkinsonism Relat Disord. 2014;20(9): PMID: Patel N, Ondo W, Jimenez-Shahed J. Habituation and rebound to thalamic deep brain stimulation in long-term management of tremor associated with demyelinating neuropathy. Int J Neurosci. 2014;124(12): PMID: Waln O, Jimenez-Shahed J. Rechargeable deep brain stimulation implantable pulse generators in movement disorders: patient satisfaction and conversion parameters. Neuromodulation. 2014;17(5):425-30; discussion 430. PMID: Wijemanne S, Jimenez-Shahed J. Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle. Parkinsonism Relat Disord. 2014;20(10): PMID: Zhu XY, Pan TH, Ondo WG, Jimenez-Shahed J, Wu YC. Effects of deep brain stimulation in relatively young-onset multiple system atrophy Parkinsonism. J Neurol Sci. 2014;342(1-2):42-4. PMID: Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opin Orphan Drugs. 2013;1(5): DOI: / Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2): PMID: Strickland BA, Jimenez-Shahed J, Jankovic J, Viswanathan A. Radiofrequency lesioning through deep brain stimulation electrodes: a pilot study of lesion geometry and temperature characteristics. J Clin Neurosci. 2013;20(12): PMID: Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxina (Xeomin(R)), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat. 2012;8: PMID: Ondo WG, Jankovic J, Simpson R, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012;13(9): PMID: Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012;90(4): PMID: Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70-3. PMID: Kuo SH, Jimenez-Shahed J. Topiramate in treatment of tourette syndrome. Clin Neuropharmacol. 2010;33(1):32-4. PMID: Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009;24(4): PMID: Jimenez-Shahed J. Tourette syndrome. Neurol Clin. 2009;27(3):737-55, vi. PMID: Kuo SH, Vullaganti M, Jimenez-Shahed J, Kwan JY. Camptocormia as a presentation of generalized inflammatory myopathy. Muscle Nerve. 2009;40(6): PMID: Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008;430(1): PMID: Kenney C, Kuo SH, Jimenez-Shahed J. Tourette's syndrome. Am Fam Physician. 2008;77(5): PMID: Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22(12): PMID: Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007;260(1-2): PMID: Poysky J, Jimenez-Shahed J. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2007;22(9):1366-7; author reply PMID: Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism

4 (Page 4 of 7) Relat Disord. 2007;13(2): PMID: Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007;68(2): PMID: Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21(5): PMID: Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001;16(1): PMID: BOOK CHAPTERS and OTHER PUBLICATIONS Jimenez-Shahed J. Cerebellar disease. In: Kass JS, Mizrahi EM, editors. Neurology secrets. 6th ed. Philadelphia: Elsevier; p Jimenez-Shahed J, Jankovic J. Childhood movement disorders. In: Gilman S, editor. Neurology-Medlink. Arbor Publishing, La Jolla, CA; Annual updates Available from: Shahed J, Jankovic J. Introduction to dystonia. In: Stacy M, editor. Handbook of dystonia. 2nd ed. New York: Informa Healthcare; Shahed J, Jankovic J. An elderly lady with ataxia and neuropathy. In: Reich SG, editor. Movement disorders: 100 instructive cases. London: Martin Dunitz Ltd; Shahed J, Jankovic J. Internet dyskinesia in Parkinson's disease. In: Reich SG, editor. Movement disorders: 100 instructive cases. London: Martin Dunitz Ltd; Shahed J, Jankovic J. Introduction to dystonia. In: Stacy M, editor. Handbook of dystonia. New York: Informa Healthcare; Shahed J, Jankovic J. Motor symptoms in Parkinson's disease. In: Koller WC, Melamed E, editors. Parkinson's disease and related disorders. Vol. 1. Amsterdam: Elsevier; p POSTER and PLATFORM PRESENTATIONS Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, et al. Confirmed safety of deutetrabenazine for tardive dyskinesia in a 2-year open-label extension study. Presented at the American Academy of Neurology (AAN), 70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018). Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, et al. Long-term treatment with deutetrabenazine is associated with continued improvement in tardive dyskinesia (TD): Results from an open-label extension study. Presented at the American Academy of Neurology (AAN), 70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018). Jimenez-Shahed J, Bressman S, Burack M, Farace E, McInerney J, Kirk J, et al. RAD-PD: Registry for the advancement of DBS in Parkinson's disease. Presented at the American Academy of Neurology (AAN), 70th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018). Kim SH, Sander A, Jimenez-Shahed J, York MK. Self-efficacy, life satisfaction, mood, and functional outcomes for the PD-CoRE program. Presented at the American Congress of Rehabilitation Medicine (ACRM), 94th Annual Conference in Atlanta, Ga. (Oct , 2017). Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Addressing involuntary movements in tardive dyskinesia (aim-td): Efficacy, safety, and tolerability of fixed-dose deutetrabenazine for the treatment of tardive dyskinesia. Mov Disord. 2017;32 Suppl 2:S277. [Previous presented] Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Effect of deutetrabenazine on QTcF interval in the AIM-TD study: A 12-week, phase III, randomized, double-blind, placebo-controlled study. Mov Disord. 2017;32 Suppl 2:S Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study. Mov Disord. 2017;32 Suppl 2:S270. [Previous presented] Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al. Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study. Mov Disord. 2017;32 Suppl 2:S [Previous presented] Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies. Mov Disord. 2017;32 Suppl 2:S276. [Previous presented] Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials. Mov Disord. 2017;32 Suppl 2:S273. [Previous presented] Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies. Mov Disord. 2017;32 Suppl 2:S271. [Previous presented]

5 (Page 5 of 7) Jimenez-Shahed J, Fernandez H, Hauser R, Davis M, Factor S, Isojärvi J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in clinical global impression of change (CGIC) with deutetrabenazine treatment in tardive dyskinesia (TD). Mov Disord. 2017;32 Suppl 2:S275. [Previous presented] Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al. Deutetrabenazine is associated with an improvement in involuntary movements in patients with tardive dyskinesia (TD) as seen by the high proportion of responders to deutetrabenazine treatment in the AIM-TD study. Mov Disord. 2017;32 Suppl 2:S274. [Previous presented] Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al. Deutetrabenazine treatment response by concomitant dopamine-receptor antagonists in the phase III, randomized, double-blind, placebo-controlled AIM-TD trial in tardive dyskinesia (TD). Mov Disord. 2017;32 Suppl 2:S [Previous presented] Anderson K, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study. Presented at the American Psychiatric Association (APA), 170th Annual Meeting in San Diego, Calif. (May 20-24, 2017). Factor S, Anderson K, Stamler D, Davis M, Hauser R, Isojärvi J, et al. Effect of deutetrabenazine on quality of life in patients with tardive dyskinesia in AIM-TD, a 12-week double-blind, placebo-controlled study. Presented at the American Psychiatric Association (APA), 170th Annual Meeting in San Diego, Calif. (May 20-24, 2017). Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Effect of deutetrabenazine by body region score of the abnormal involuntary movement scale in tardive dyskinesia: ARM-TD and AIM-TD studies. Presented at the American Psychiatric Association (APA), 170th Annual Meeting in San Diego, Calif. (May 20-24, 2017). Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Evaluation of patient-reported outcomes in tardive dyskinesia patients with underlying psychotic and mood disorders in the ARM-TD and AIM-TD trials. Presented at the American Psychiatric Association (APA), 170th Annual Meeting in San Diego, Calif. (May 20-24, 2017). Fernandez H, Stamler D, Davis M, Factor S, Hauser R, Isojärvi J, et al. Improvements in clinical global impression of change with deutetrabenazine treatment in tardive dyskinesia from the ARM-TD and AIM-TD studies. Presented at the American Psychiatric Association (APA), 170th Annual Meeting in San Diego, Calif. (May 20-24, 2017). Anderson KE, Factor SA, Davis MD, Hauser RA, Isojarvi J, Jimenez-Shahed J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): Effect of fixed-dose deutetrabenazine by baseline comorbidities. Neurology. 2017;88(16 Suppl):S [Platform Presentation] Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): Efficacy, safety, and tolerability of fixed-dose deutetrabenazine for the treatment of moderate to severe tardive dyskinesia (TD). Neurology. 2017;88(16 Suppl):S [Platform Presentation] Fernandez HH, Hauser RA, Davis MD, Factor SA, Isojarvi J, Jimenez-Shahed J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in clinical global impression of change (CGIC) with deutetrabenazine treatment in moderate to severe tardive dyskinesia (TD). Neurology. 2017;88(16 Suppl):S [Platform Presentation] Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al. Deutetrabenazine is associated with an improvement in involuntary movements in patients with tardive dyskinesia (TD) as seen by the high proportion of responders to deutetrabenazine treatment in the AIM-TD study. Neurology. 2017;88(16 Suppl):P Jimenez-Shahed J, Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, et al. Deutetrabenazine treatment response by concomitant dopamine-receptor antagonists in the phase III, randomized, double-blind, placebo-controlled AIM-TD trial in tardive dyskinesia (TD). Neurology. 2017;88(16 Suppl):P Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo W, LeDoux MS, et al. A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD). Mov Disord. 2016;31 Suppl 2:S294. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy TK, Shprecher D, et al. A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome. Mov Disord. 2016;31 Suppl 2:S307. Jimenez-Shahed J, Itin I, Mehanna R. One to 40 years later: Delayed effects of brain radiation presenting as parkinsonism. Mov Disord. 2016;31 Suppl 2:S291. Jimenez-Shahed J, Telkes I, Viswanathan A, Ince NF. Globus pallidus interna oscillatory activity differentiates tics from voluntary movements and the Parkinsonian resting state. Mov Disord. 2016;31 Suppl 2:S388. Farcas A, Jimenez Shahed J. Success of targeting rationale in deep brain stimulation for Parkinson's disease. Neurology. 2016;86(Meeting Abstracts 1):P Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, et al. A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome. Neurology. 2016;86(Meeting Abstracts 1):P Niemann N, Strutt A, Viswanathan A, Jimenez Shahed J. Safety profile of unblinded internal pallidal deep brain stimulation for medically refractory Tourette syndrome. Neurology. 2016;86(Meeting Abstracts 1):P Tarakad A, Jimenez Shahed J. Paradoxical worsening dystonia after deep brain stimulation in a patient with neurodegeneration with brain iron accumulation. Neurology. 2016;86(Meeting Abstracts 1):P1.013.

6 (Page 6 of 7) Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, et al. A randomized controlled trial of telemedicine for Parkinson's disease (Connect.Parkinson) in the United States: Interim assessment of investigator and participant experiences. Mov Disord. 2015;30 Suppl 1:S64. Jimenez-Shahed J, Keller J, Hunter C, Jankovic J. DBS experience at a tertiary care referral center. Mov Disord. 2015;30 Suppl 1:S223. Shah D, Jimenez-Shahed J. Clinical characteristics of tetrabenazine-induced parkinsonism. Mov Disord. 2015;30 Suppl 1:S297. Jimenez-Shahed J, Viswanath H, Velasquez K, Ramirez-Castaneda J, Baldwin P, Salas R. Impulsivity and resting state functional connectivity of the supplementary motor area in Parkinson's disease. Mov Disord. 2014;29 Suppl 1:866. Jimenez-Shahed J, York M, Smith-Gloyd EM, Jankovic J, Viswanathan A. MER vs. MRI guidance in placement of DBS electrodes for Parkinson's disease. Mov Disord. 2014;29 Suppl 1:1202. Luo L, Jimenez-Shahed J. Deep brain stimulation targets for the treatment of dystonic tremor. Mov Disord. 2014;29 Suppl 1:1255. Thenganatt MA, Srinivasan VM, Viswanathan A, Jimenez-Shahed J. Deep brain stimulation troubleshooting: Revision vs. reprogramming. Stereotact Funct Neurosurg. 2014;92(suppl 1): 52. Waln O, Jimenez-Shahed J. Constant voltage versus constant current deep brain stimulation: Is impedance fluctuation sufficient to favor constant current stimulation? Mov Disord. 2014;29 Suppl 1:1237. Jimenez-Shahed J, Waln O. Use of interleaving in deep brain stimulator programming in patients with movement disorders. Neurology. 2014;82(Meeting Abstracts 1):P Shah DP, Jimenez-Shahed J. Clinical manifestations of tolerance to deep brain stimulation. Neurology. 2014;82(Meeting Abstracts 1):P Waln O, Jimenez-Shahed J. Clinical significance of abnormal electrode impedance readings in deep brain stimulation for treatment of movement disorders. Neurology. 2014;82(Meeting Abstracts 1):P [Previously Presented] Wijemanne S, Waln O, Jimenez-Shahed J. Concurrent bilateral Vim and STN DBS in a patient with ET/PD. Neurology. 2014;82(Meeting Abstracts 1):P Waln O, Jimenez-Shahed J. Clinical significance of abnormal electrode impedance readings in deep brain stimulation for treatment of movement disorders. Mov Disord. 2013;28(10):e3. Waln O, Jimenez-Shahed J. Constant voltage versus constant current deep brain stimulation: Is impedance fluctuation significant to favor constant current stimulation? Mov Disord. 2013;28(10):e3. Baizabal-Carvallo JF, Kagnoff M, Jimenez-Shahed J, Fekete R, Jankovic J. The long-term safety and efficacy of thalamic deep brain stimulation in essential tremor. Mov Disord. 2013;28 Suppl 1:S430. Patel N, Ondo W, Jimenez-Shahed J. Habituation and rebound to thalamic DBS in long-term management of tremor associated with demyelinating sensorimotor peripheral neuropathy. Mov Disord. 2013;28 Suppl 1:S Patel N, Richter A, Donovan D, Jimenez-Shahed J. Unilateral ventral intermediate deep brain stimulation improves spasmodic dysphonia. Mov Disord. 2013;28 Suppl 1:S433. Kagnoff M, Jimenez Shahed J. Improvement in cortical myoclonus in a patient with VIM deep brain stimulation for essential tremor. Neurology. 2013;80(Meeting Abstracts 1):P Patel N, Jimenez Shahed J. Simultaneous improvement of tics and drug-induced parkinsonism after Gpi DBS: A case report. Neurology. 2013;80(Meeting Abstracts 1):IN Patel N, York M, Phan C, Jimenez Shahed J. Identifying the correlates of pseudobulbar affect in patients with parkinsonian disorders and ALS. Neurology. 2013;80(Meeting Abstracts 1):P Wijemanne S, Jimenez Shahed J. Improvement in camptocormia following botulinum toxin injection to the external oblique muscle. Neurology. 2013;80(Meeting Abstracts 1):P Mehanna R, Hunter C, Davidson A, Ondo W, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2012;27(Suppl 1):S457. Morgan L, Jimenez-Shahed J, Todaro V, Welsh M. Parkinson's advocates in research: The impact of peer-to-peer education and outreach on Parkinson's study inquiry and enrollment among people with Parkinson's and care partners. Mov Disord. 2012;27(Suppl 1):S143. Ondo WG, Jankovic J, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Mov Disord. 2012;27(Suppl 1):S404. York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(Suppl 1):S172. [Previously Presented] Patel N, Ondo W, Jimenez-Shahed J. A case control series of thalamic DBS in patients with demyelinating neuropathy and medication refractory tremors. Mov Disord. 2012;27(4):e4. York MK, Marsh L, Jimenez-Shahed J, Okun M, Moro E, Hunter C, et al. Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real world pre-operative practice patterns. Mov Disord. 2012;27(4):e12.

7 (Page 7 of 7) Jimenez Shahed J, Scott B, Strutt A. Long-term neuropsychological follow-up in pallidal stimulation for medically-refractory Tourette syndrome. Neurology. 2012;78(Meeting Abstracts 1):P Waln O, Jimenez Shahed J, Juliet Wendt, York M, Baizabal Carvallo J, Mehanna R, et al. Diagnostic reliability of DaTscan in movement disorders. Neurology. 2012;78(Meeting Abstracts 1):P Waln O, Jimenez Shahed J. Use of rechargeable DBS implantable pulse generators in patients with movement disorders: Patient satisfaction and stimulation parameters. Neurology. 2012;78(Meeting Abstracts 1):P Jimenez-Shahed J. Programming parameters and outcome in GPi deep brain stimulation (DBS) for Tourette syndrome (TS). Mov Disord. 2011;26 Suppl 2:S88-9. Elliott R, Todaro V, Cook M, Jimenez-Shahed J, Kavanagh P, Thomas CA, et al. Peer-to-peer clinical research outreach and education: A model for increasing clinical study awareness, inquiry and enrollment among people with Parkinson's. Neurology. 2011;76(Suppl 4):A44. Jankovic J, Jimenez-Shahed J, Brown LW. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Mov Disord. 2009;24 Suppl 1:S497. Jimenez-Shahed J, Baker K, Davidson A, Jankovic J. The role of dopaminergic medication doses in impulse control disorders (ICD) in Parkinson's disease (PD). Mov Disord. 2008;23 Suppl 1:S82. Kuo SH, Jimenez-Shahed J. Topiramate in treatment of Tourette's syndrome (TS). Mov Disord. 2008;23 Suppl 1:S Jimenez-Shahed J, Calhoun K, Davidson A, Jankovic J. Craving for sweets and other compulsive behaviors in patients with Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A Jimenez-Shahed J, Hunter CB, Jankovic J. Acamprosate improves impulse control disorders in Parkinson's disease. Neurology. 2008;70(11 Suppl 1):A288. Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. Motor and behavioral outcomes after bilateral GPi deep brain stimulation for severe Tourette syndrome. Mov Disord. 2007;22 Suppl 16:S283. Cheung MC, Shahed J, Jankovic J. Malignant Tourette syndrome. Neurology. 2007;68(12 Suppl 1):A155. Deng H, Le W, Shahed J, Jankovic J. Three parkin mutations in a family with Parkinson's disease. Neurology. 2007;68(12 Suppl 1):A323. Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. Mov Disord. 2006;21 Suppl 15:S668. Shahed J, Davidson A, Jankovic J. Craving sweets in Parkinson's disease. Mov Disord. 2006;21 Suppl 15:S599. Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J. GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric co-morbidities. Mov Disord. 2006;21 Suppl 15:S693. Shahed J, Poysky J, Kenney C, Simpson Jr RK, Jankovic J. Bilateral GPI deep brain stimulation for Tourette syndrome. Neurology. 2006;66(5 Suppl 2):A366. Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Neurology. 2005;64(6 Suppl 1):A255. [Previously Presented] Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J. Gait and balance assessment in parkinsonian disorders. Mov Disord. 2005;20 Suppl 10:S Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2005;20 Suppl 10:S Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Mov Disord. 2005;20 Suppl 10:S